Amendments to the Claims:

Please cancel claims 1-6, 8-10, and 12; please amend claims 7, 13-14, and 16 as summarized below.

Claim 1. (canceled)

Claim 2. (canceled)

Claim 3. (canceled)

Claim 4. (canceled)

Claim 5. (canceled)

Claim 6. (canceled)

Claim 7. (amended) A FLINT analog resistant to proteolysis at position 218 of SEQ ID NO:1 comprising an amino acid substitution in SEQ ID NO:1, selected from the group consisting of:

    a. Arg at position 218 is replaced by Gln

    b. Arg at position 218 is replaced by Glu;

    c. ~~Thr at position 216 is replaced by Pro;~~

    d. Arg at position 218 is replaced by Ala;

    e. Arg at position 218 is replaced by Gly;

    f. Arg at position 218 is replaced by Ser;

    g. Arg at position 218 is replaced by Val;

    h. Arg at position 218 is replaced by Tyr; and

    i. Arg at position 218 is replaced by Asn; ~~and~~

    j. ~~Pro at position 217 is replaced by Tyr.~~

Claim 8. (canceled)

Claim 9. (canceled)

Claim 10. (canceled)

Claim 11. (canceled)

Claim 12. (canceled)

Claim 13. (amended) A FLINT analog ~~as in Claim 1~~ wherein Thr at position 216 of SEQ ID NO:1 is replaced by Pro, and Arg at position 218 is replaced by Gln.

Claim 14. (amended) A method to treat or prevent a disease or condition in a mammal comprising the administration of a therapeutically effective amount of a protease resistant FLINT analog of claim ~~2~~ 7 or claim 13.

Claim 15. (original) A method as in Claim 14 wherein said disease or condition is acute lung injury, acute respiratory distress syndrome, or ulcerative colitis.

Claim 16. (amended) A pharmaceutical formulation comprising as an active ingredient a protease resistant FLINT analog of claim 2 7 or claim 13 associated with one or more pharmaceutically acceptable carriers, excipients, or diluents thereof.

Claim 17-20 (canceled).

Claim 21. (original) A FLINT analog resistant to proteolysis at position 218 of SEQ ID NO:1 comprising the amino acid sequence of SEQ ID NO:1, wherein Arg at position 218 is substituted by Gln.

Claims 22-23 (canceled)